(2S)-2-{[(2S)-1-[(3R,6S,9S,12S,15S)-12-[(2S)-butan-2-yl]-9-(2-carbamoylethyl)-6-(carbamoylmethyl)-15-[(4-hydroxyphenyl)methyl]-16-methyl-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosane-3-carbonyl]pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)-4-methylpentanamide

• ChemBase编号: 1140
• 分子式: C45H69N11O12S
• 平均质量: 988.16086
• 单一同位素质量: 987.4847877
• SMILES: S1C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](N(C(=O)CCC1)C)Cc1ccc(O)cc1)[C@H](CC)C)CCC(=O)N)CC(=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N
• Canonical SMILES: CC[C@@H]([C@@H]1NC(=O)[C@H](Cc2ccc(cc2)O)N(C)C(=O)CCCSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC1=O)CCC(=O)N)CC(=O)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N)CC(C)C)C
• InChI: InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(67)50-28(15-16-34(46)58)40(63)51-30(21-35(47)59)41(64)53-31(23-69-18-8-10-37(61)55(5)33(43(66)54-38)20-26-11-13-27(57)14-12-26)45(68)56-17-7-9-32(56)42(65)52-29(19-24(2)3)39(62)49-22-36(48)60/h11-14,24-25,28-33,38,57H,6-10,15-23H2,1-5H3,(H2,46,58)(H2,47,59)(H2,48,60)(H,49,62)(H,50,67)(H,51,63)(H,52,65)(H,53,64)(H,54,66)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1
• InChIKey: SMMBGKXBHJTULT-DTRKZRJBSA-N

名称和登记号

名称

• IUPAC标准名: (2S)-2-{[(2S)-1-[(3R,6S,9S,12S,15S)-12-[(2S)-butan-2-yl]-9-(2-carbamoylethyl)-6-(carbamoylmethyl)-15-[(4-hydroxyphenyl)methyl]-16-methyl-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosane-3-carbonyl]pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)-4-methylpentanamide
• IUPAC传统名: (2S)-2-{[(2S)-1-[(3R,6S,9S,12S,15S)-12-[(2S)-butan-2-yl]-9-(2-carbamoylethyl)-6-(carbamoylmethyl)-15-[(4-hydroxyphenyl)methyl]-16-methyl-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosane-3-carbonyl]pyrrolidin-2-yl]formamido}-N-(carbamoylmethyl)-4-methylpentanamide; carbetocin
• 商标名: Duratocin; Duratocin, Pabal, Lonactene
• 别名: Carbetocinum [inn-latin]; Carbetocino [inn-spanish]; Carbetocin

登记号

• CAS号: 37025-55-1
• PubChem SID: 160964603
• PubChem CID: 71715
• ATC码: H01BB03
• Chemspider ID: 64765
• DrugBank ID: DB01282
• KEGG ID: D07229
• 美国药典/FDA物质标识码: 88TWF8015Y
• 维基百科标题: Carbetocin

理论计算性质

JChem

• Acid pKa: 9.499266
• 质子受体: 12
• 质子供体: 10
• LogD (pH = 5.5): -3.506033
• LogD (pH = 7.4): -3.5094075
• Log P: -3.5059896
• 摩尔折射率: 250.5991 cm^3
• 极化性: 97.95759 Å^3
• 极化表面积: 364.72 Å^2
• 可自由旋转的化学键: 17
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: 0.29
• LOG S: -4.32
• 溶解度: 4.69e-02 g/l

分子性质

理化性质

• 疏水性(logP): -2

药理学性质

• 给药途径: Intravenous, intramuscular
• 生物利用度: 80% (IM)
• 半衰期: 40 minutes
• 法定药品分级: Not available (U.S.); POM (UK)

详细说明

DrugBank - DB01282

• Drug Groups: approved
• Description: Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus.
• Indication: Used to control postpartum hemorrhage and bleeding after giving birth.
• Pharmacology: Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is sold under the trade name Duratocin. It is an analogue of oxytocin, and its action is similar to that of oxytocin; it causes contraction of the uterus.
• Affected Organisms: Humans and other mammals
• Absorption: Bioavailability is 80% following intramuscular injection.
• Half Life: 40 minutes
• External Links: Wikipedia